Seven Fleet Capital Management LP Raises Holdings in Madrigal Pharmaceuticals, Inc. $MDGL

Seven Fleet Capital Management LP raised its stake in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) by 82.4% in the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 3,393 shares of the biopharmaceutical company’s stock after purchasing an additional 1,533 shares during the quarter. Seven Fleet Capital Management LP’s holdings in Madrigal Pharmaceuticals were worth $1,776,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. Flagship Harbor Advisors LLC bought a new position in shares of Madrigal Pharmaceuticals in the fourth quarter worth approximately $29,000. Kemnay Advisory Services Inc. bought a new stake in Madrigal Pharmaceuticals during the 4th quarter valued at $39,000. Quarry LP bought a new stake in Madrigal Pharmaceuticals during the 3rd quarter valued at $39,000. Accent Capital Management LLC boosted its position in Madrigal Pharmaceuticals by 64.9% during the 4th quarter. Accent Capital Management LLC now owns 94 shares of the biopharmaceutical company’s stock valued at $55,000 after buying an additional 37 shares during the period. Finally, Johnson Financial Group Inc. purchased a new stake in Madrigal Pharmaceuticals during the 3rd quarter valued at $50,000. Hedge funds and other institutional investors own 98.50% of the company’s stock.

Wall Street Analyst Weigh In

MDGL has been the topic of a number of recent analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Madrigal Pharmaceuticals in a report on Friday, July 17th. UBS Group reiterated a “buy” rating on shares of Madrigal Pharmaceuticals in a report on Friday. HC Wainwright reissued a “buy” rating on shares of Madrigal Pharmaceuticals in a research note on Friday. Canaccord Genuity Group raised their target price on Madrigal Pharmaceuticals from $578.00 to $587.00 and gave the stock a “buy” rating in a research note on Wednesday. Finally, Evercore set a $649.00 price target on Madrigal Pharmaceuticals in a report on Thursday, May 7th. Fourteen investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $688.20.

Key Madrigal Pharmaceuticals News

Here are the key news stories impacting Madrigal Pharmaceuticals this week:

• Positive Sentiment: Rezdiffra continues to drive strong revenue growth. Second-quarter revenue reached $364.25 million, up 71.2% year over year and above the $352.13 million analyst consensus, reflecting continued demand for the company’s MASH drug. Madrigal Pharmaceuticals Reports Second-Quarter 2026 Financial Results and Provides Corporate Updates
• Positive Sentiment: The quarterly loss was narrower than expected. Madrigal reported a loss of $1.99 per share, beating estimates ranging from $2.55 to $2.68 per share, although the loss was wider than the $1.90-per-share loss recorded a year earlier. Madrigal Reports Q2 Loss, Beats Revenue Estimates
• Positive Sentiment: Analyst support remains favorable. Wells Fargo assigned Madrigal an Overweight rating, providing a positive signal for the company’s outlook. Madrigal Earns Overweight Rating from Wells Fargo
• Neutral Sentiment: Madrigal’s earnings call and quarterly presentation highlighted Rezdiffra’s contribution to the business and the company’s ongoing development efforts, but investors are weighing the pace of the commercial launch against the stock’s elevated valuation. Madrigal Q2 2026 Earnings Call Transcript
• Negative Sentiment: Shares fell despite the earnings beat. Investors appear concerned that Rezdiffra’s commercial growth is moderating, making the strong year-over-year revenue increase less compelling and raising expectations for evidence of sustained prescribing and sales momentum. MDGL Stock Down Despite Q2 Beat

Insider Activity

In other Madrigal Pharmaceuticals news, insider David Soergel sold 1,042 shares of the firm’s stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $495.74, for a total value of $516,561.08. Following the completion of the sale, the insider directly owned 10,033 shares in the company, valued at $4,973,759.42. This trade represents a 9.41% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Richard S. Levy sold 5,682 shares of Madrigal Pharmaceuticals stock in a transaction that occurred on Friday, May 22nd. The shares were sold at an average price of $515.44, for a total value of $2,928,730.08. Following the sale, the director directly owned 22,015 shares in the company, valued at approximately $11,347,411.60. The trade was a 20.51% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 7,568 shares of company stock worth $3,880,711 in the last quarter. 17.60% of the stock is owned by corporate insiders.

Madrigal Pharmaceuticals Stock Performance

NASDAQ:MDGL opened at $467.32 on Friday. The company has a quick ratio of 3.16, a current ratio of 3.50 and a debt-to-equity ratio of 0.63. The firm’s fifty day simple moving average is $516.48 and its 200 day simple moving average is $499.05. The stock has a market cap of $10.78 billion, a P/E ratio of -36.25 and a beta of -1.05. Madrigal Pharmaceuticals, Inc. has a twelve month low of $290.00 and a twelve month high of $615.00.

Madrigal Pharmaceuticals (NASDAQ:MDGL) last issued its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported ($1.99) EPS for the quarter, topping the consensus estimate of ($2.68) by $0.69. Madrigal Pharmaceuticals had a negative net margin of 25.32% and a negative return on equity of 55.04%. The business had revenue of $364.25 million during the quarter, compared to analyst estimates of $352.13 million. During the same period in the prior year, the business earned ($1.90) EPS. The company’s revenue for the quarter was up 71.2% on a year-over-year basis. As a group, research analysts predict that Madrigal Pharmaceuticals, Inc. will post -7.47 EPS for the current year.

Madrigal Pharmaceuticals Profile

Madrigal Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the development of innovative therapies for cardiovascular, metabolic and liver diseases. The company’s pipeline centers on novel, liver-directed agents designed to address significant unmet medical needs, with an emphasis on nonalcoholic steatohepatitis (NASH) and related metabolic disorders.

The lead product candidate, resmetirom (MGL-3196), is an orally administered, selective thyroid hormone receptor-β agonist in Phase 3 development for the treatment of NASH.